Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
569 participants
INTERVENTIONAL
2010-04-30
2010-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Vitamin D Supplementation and the Immune Response
NCT01893385
Vitamin D, Blood Pressure, Lipids, Infection and Depression
NCT00960232
Trial of Vitamin D Supplementation for the Prevention of Influenza and Other Respiratory Infections (ViDiFlu)
NCT01069874
Vitamin D and COVID-19 Management
NCT04385940
Vitamin D Supplementation for the Prevention of Acute Respiratory Tract Infections
NCT00973583
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
cholecalciferol
cholecalciferol in doses 800-6000 IU per day
choleclaciferol
800-6000 IU cholecalciferol per day
placebo
placebo identical looking as cholecalciferol capsules
choleclaciferol
800-6000 IU cholecalciferol per day
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
choleclaciferol
800-6000 IU cholecalciferol per day
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
20 Years
80 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Tromso
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
University of Tromsø
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
rolf Jorde, md
Role: PRINCIPAL_INVESTIGATOR
University of Tromso, Norway
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Tromsø
Tromsø, Tromsø, Norway
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
UIT-ENDO-2010-1
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.